{"id":53638,"date":"2026-01-11T20:59:32","date_gmt":"2026-01-11T12:59:32","guid":{"rendered":"https:\/\/flcube.com\/?p=53638"},"modified":"2026-01-11T20:59:33","modified_gmt":"2026-01-11T12:59:33","slug":"remegens-rc48-wins-fourth-breakthrough-therapy-designation-for-gastric-cancer-combo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53638","title":{"rendered":"RemeGen&#8217;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo"},"content":{"rendered":"\n<p><strong>RemeGen Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA: 688331<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>) announced that its core product, <strong>Disitamab Vedotin (RC48\/Aidixi)<\/strong>, has been granted its <strong>fourth Breakthrough Therapy Designation (BTD)<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The designation applies to <strong>first\u2011line treatment<\/strong> of <strong>HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong> in combination with <strong>trastuzumab<\/strong> and <strong>toripalimab<\/strong>, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-milestone\">Product &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Disitamab Vedotin (RC48\/Aidixi)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>RemeGen Ltd (688331.SH\/9995.HK)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>HER2\u2011targeted antibody\u2011drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>4th Breakthrough Therapy Designation (CDE\/NMPA)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>1L HER2\u2011high GC\/GEJC with trastuzumab + toripalimab<\/td><\/tr><tr><td><strong>Previous BTDs<\/strong><\/td><td>3 prior BTDs (gastric 3L, urothelial carcinoma, breast cancer)<\/td><\/tr><tr><td><strong>Regulatory History<\/strong><\/td><td>Conditionally approved June\u202f2021 (3L gastric), Dec\u202f2021 (2L urothelial), Apr\u202f2025 (breast cancer liver mets)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-differentiation\">Clinical Evidence &amp; Differentiation<\/h2>\n\n\n\n<p><strong>RC48\u2019s Clinical Profile<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2 Specificity<\/strong>: Targets HER2\u2011overexpressing tumors (IHC 2+\/3+)<\/li>\n\n\n\n<li><strong>Payload<\/strong>: Microtubule inhibitor MMAE with bystander effect<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong>: Synergizes with <strong>trastuzumab<\/strong> (HER2 mAb) and <strong>toripalimab<\/strong> (PD\u20111 inhibitor) for <strong>dual HER2 blockade + immune activation<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Significance<\/strong>: This marks the <strong>first BTD for a HER2 ADC triple\u2011combination<\/strong> in first\u2011line gastric cancer, addressing a <strong>\u00a58\u201110\u202fbillion<\/strong> market opportunity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-her2-positive-gastric-cancer\">Market Opportunity: HER2\u2011Positive Gastric Cancer<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GC Incidence<\/strong>: <strong>~480,000<\/strong> new cases annually (50% of global total)<\/li>\n\n\n\n<li><strong>HER2\u2011High Expression<\/strong>: <strong>15\u201120%<\/strong> of GC patients \u2192 <strong>~72,000\u201196,000<\/strong> eligible<\/li>\n\n\n\n<li><strong>First\u2011Line Setting<\/strong>: <strong>60\u201170%<\/strong> of eligible patients receive first\u2011line therapy \u2192 <strong>~50,000<\/strong> addressable patients<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Trastuzumab + chemotherapy (ORR\u202f\u2248\u202f47%, mOS\u202f\u2248\u202f13.5\u202fmonths)<\/li>\n<\/ul>\n\n\n\n<p><strong>RC48 Revenue Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026 Launch<\/strong>: <strong>\u00a5500\u2011800\u202fmillion<\/strong> (partial year)<\/li>\n\n\n\n<li><strong>2027 Peak<\/strong>: <strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (assuming 15\u201120% market share)<\/li>\n\n\n\n<li><strong>Ex\u2011China Opportunity<\/strong>: <strong>\u00a55\u20117\u202fbillion<\/strong> potential via partnerships (US\/EU rights still available)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage (China)<\/th><th>Key Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>RC48<\/strong><\/td><td><strong>RemeGen<\/strong><\/td><td>HER2 ADC + combo<\/td><td><strong>4x BTD<\/strong><\/td><td><strong>First triple\u2011combo BTD<\/strong><\/td><\/tr><tr><td><strong>Enhertu<\/strong><\/td><td>Daiichi\/AZ<\/td><td>HER2 ADC<\/td><td>Approved (3L)<\/td><td>Moving to 1L, monotherapy focus<\/td><\/tr><tr><td><strong>Keytruda + chemo<\/strong><\/td><td>MSD<\/td><td>PD\u20111 + chemo<\/td><td>Approved<\/td><td>No HER2 targeting<\/td><\/tr><tr><td><strong>Toripalimab + chemo<\/strong><\/td><td>Junshi<\/td><td>PD\u20111 + chemo<\/td><td>Approved<\/td><td>No HER2 ADC component<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: RC48\u2019s <strong>ADC + mAb + PD\u20111<\/strong> triple combination offers <strong>synergistic HER2 blockade<\/strong> and <strong>immune activation<\/strong>, potentially <strong>superior to monotherapy or doublets<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>For RemeGen<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: 4 BTDs establish <strong>leadership in HER2 ADC innovation<\/strong><\/li>\n\n\n\n<li><strong>NRDL Pathway<\/strong>: BTD enables <strong>priority review (130 days)<\/strong> and <strong>2027 NRDL negotiation<\/strong><\/li>\n\n\n\n<li><strong>Global Licensing<\/strong>: Ex\u2011China rights for RC48 remain <strong>available<\/strong>, with potential <strong>$800M\u20111.2B deal<\/strong> value<\/li>\n\n\n\n<li><strong>Pipeline Leverage<\/strong>: Success supports <strong>RC88 (HER2 ADC for breast cancer)<\/strong> and <strong>RC108 (c\u2011Met ADC)<\/strong> programs<\/li>\n<\/ul>\n\n\n\n<p><strong>For China Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety Standard<\/strong>: RC48\u2019s <strong>manageable toxicity<\/strong> (ocular events, neuropathy) vs. competitors<\/li>\n\n\n\n<li><strong>Cost\u2011Effectiveness<\/strong>: Triple combo projected at <strong>\u00a5180,000\u2011220,000<\/strong> per patient, <strong>competitive<\/strong> with PD\u20111 + chemo alone<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: <strong>Yantai facility<\/strong> (capacity: 500\u202fkg\/year) ready for commercial scale<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China GC Patients Treated<\/strong><\/td><td>8,000<\/td><td>15,000<\/td><td>25,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>16%<\/td><td>30%<\/td><td>42%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>1,440<\/td><td>2,700<\/td><td>3,780<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>85%<\/td><td>87%<\/td><td>88%<\/td><\/tr><tr><td><strong>Royalty to Partners<\/strong><\/td><td>12%<\/td><td>10%<\/td><td>8% (trastuzumab + toripalimab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Valuation<\/strong>: RC48 could contribute <strong>\u00a545\u201150 per share<\/strong> to RemeGen\u2019s valuation, representing <strong>30\u201135% upside<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding RC48\u2019s clinical development, regulatory approvals, market penetration, and revenue forecasts. Actual results may differ materially due to competitive dynamics, pricing negotiations, NRDL inclusion outcomes, and partnership discussions for ex\u2011China rights.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,16,1155,375,1294],"class_list":["post-53638","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-cancer","tag-hkg-9995","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen&#039;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53638\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen&#039;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo\" \/>\n<meta property=\"og:description\" content=\"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53638\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T12:59:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T12:59:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen&#8217;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo\",\"datePublished\":\"2026-01-11T12:59:32+00:00\",\"dateModified\":\"2026-01-11T12:59:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"Cancer\",\"HKG: 9995\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53638#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53638\",\"name\":\"RemeGen's RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-11T12:59:32+00:00\",\"dateModified\":\"2026-01-11T12:59:33+00:00\",\"description\":\"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\\\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53638\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53638#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen&#8217;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen's RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53638","og_locale":"en_US","og_type":"article","og_title":"RemeGen's RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo","og_description":"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.","og_url":"https:\/\/flcube.com\/?p=53638","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T12:59:32+00:00","article_modified_time":"2026-01-11T12:59:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53638#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53638"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen&#8217;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo","datePublished":"2026-01-11T12:59:32+00:00","dateModified":"2026-01-11T12:59:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53638"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Breakthrough therapy","Cancer","HKG: 9995","RemeGen","SHA: 688331"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53638#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53638","url":"https:\/\/flcube.com\/?p=53638","name":"RemeGen's RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-11T12:59:32+00:00","dateModified":"2026-01-11T12:59:33+00:00","description":"RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48\/Aidixi), has been granted its fourth Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The designation applies to first\u2011line treatment of HER2\u2011high expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and toripalimab, reinforcing RC48\u2019s leadership position in the HER2 ADC landscape.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53638#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53638"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53638#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen&#8217;s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53638"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53638\/revisions"}],"predecessor-version":[{"id":53639,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53638\/revisions\/53639"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}